William Blair Issues Pessimistic Estimate for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Research analysts at William Blair dropped their FY2025 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a research note issued to investors on Wednesday, January 15th. William Blair analyst M. Smock now expects that the medical research company will post earnings per share of $9.40 for the year, down from their prior forecast of $10.59. William Blair has a “Outperform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.18 per share.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the prior year, the firm earned $2.72 EPS. The company’s revenue was down 1.6% on a year-over-year basis.

Several other equities analysts have also issued reports on the company. Bank of America cut their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Citigroup cut Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their price target for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. TD Cowen increased their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Finally, Evercore ISI upped their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $209.00.

Charles River Laboratories International Stock Performance

CRL stock opened at $163.77 on Monday. The company has a 50 day moving average price of $189.50 and a 200 day moving average price of $198.14. Charles River Laboratories International has a fifty-two week low of $160.85 and a fifty-two week high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The stock has a market capitalization of $8.37 billion, a PE ratio of 20.50, a price-to-earnings-growth ratio of 6.62 and a beta of 1.38.

Hedge Funds Weigh In On Charles River Laboratories International

Large investors have recently made changes to their positions in the company. Wolff Wiese Magana LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter worth $32,000. Versant Capital Management Inc raised its position in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares in the last quarter. Assetmark Inc. grew its position in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. increased its stake in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in Charles River Laboratories International in the 3rd quarter valued at $59,000. Institutional investors own 98.91% of the company’s stock.

Insider Buying and Selling

In related news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).